The bill directs the Secretary of Health and Human Services to issue guidance on payment under Medicare Part B for remote monitoring devices that incorporate an artificial intelligence component and transmit information to a health care provider for management and treatment of an individual. The guidance must be issued not later than January 1, 2027, using existing CMS communication channels.
It does not by itself authorize new funding or change payment rates; instead it clarifies the criteria and processes by which AI-enabled remote monitoring devices may be considered for Medicare Part B payment. The aim is to provide clarity for manufacturers, providers, and payers to support safe innovation while maintaining Medicare program integrity.
At a Glance
What It Does
Not later than January 1, 2027, the Secretary must issue guidance on payment requirements under Part B for AI-enabled remote monitoring devices (e.g., CGMs) that include an AI component and transmit data to clinicians.
Who It Affects
Part B providers, device manufacturers, health systems using AI-enabled remote monitoring, and Medicare beneficiaries who rely on such devices for management of health conditions.
Why It Matters
Clarifies reimbursement pathways for AI-enabled devices, reducing ambiguity for providers and payers and potentially accelerating safe adoption of AI-driven remote monitoring within Medicare.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The act seeks to bring clarity to Medicare payment practices for AI-enabled remote monitoring devices. It directs the Secretary of Health and Human Services to issue guidance on how such devices—specifically those with AI components that transmit data to clinicians for patient management—should be paid under Medicare Part B.
The guidance must be released by January 1, 2027, and should utilize existing CMS communication channels. Importantly, the bill does not create new funding or explicitly change payment rates; instead, it establishes a formal process for determining payment eligibility and criteria.
This is a policy-clarity step intended to support innovation in AI-enabled devices while keeping within current Medicare authorities. For device manufacturers, providers, and payers, the guidance would define the framework they must follow when billing for AI-driven remote monitoring.
For beneficiaries, it promises more predictable coverage and access to AI-supported monitoring that informs treatment decisions.
The Five Things You Need to Know
The bill requires the Secretary to issue Medicare Part B payment guidance for AI-enabled remote monitoring devices by Jan 1, 2027.
Devices covered include remote monitoring tools with AI components (e.g.
continuous glucose monitors) that transmit data to clinicians.
Guidance must be issued using existing CMS communication channels.
No new funding or rate changes are created by the bill; it directs guidance only.
The scope centers on Part B payment rules for AI-enabled remote monitoring that informs patient management.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Sec. 1 provides the act’s cited name: Maintaining Innovation and Safe Technologies Act.
Guidance on Medicare payment for AI-enabled remote monitoring devices
Sec. 2 directs the Secretary of Health and Human Services to issue guidance on payment requirements under Part B of the Medicare program for remote monitoring devices that incorporate AI components and transmit data to providers for patient management. The guidance must be issued not later than January 1, 2027, using existing CMS communication mechanisms. The provision does not itself authorize new funding or alter payment rates; it establishes a framework for how AI-enabled remote monitoring devices should be treated under Medicare Part B.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- AI-enabled device manufacturers gain clarity on reimbursement pathways, aiding market access and product development.
- Hospitals and clinics deploying AI-powered remote monitoring can plan and bill with clearer criteria, reducing denial risk.
- Medicare beneficiaries who use AI-enabled CGMs and similar devices may experience more predictable access and reimbursement.
- Durable medical equipment suppliers gain clearer guidance for billing and supply chain planning.
- CMS and policymakers benefit from a unified, transparent framework for evaluating AI-driven monitoring technologies.
Who Bears the Cost
- HHS/CMS will need resources to develop and publish the guidance and update related policies.
- Providers and clinics may incur costs to modify billing practices and train staff to align with the guidance.
- Device manufacturers may incur costs to align product labeling and documentation with CMS guidance.
- Payers and insurers may need to adjust their administrative systems to implement the new guidance consistently.
- Health systems may incur integration costs to ensure AI-enabled devices connect with electronic health records and reporting systems in line with the guidance.
Key Issues
The Core Tension
The central tension is balancing the desire to spur AI-enabled medical innovation in remote monitoring with the need for clear, consistent Medicare payment rules that ensure appropriate use and prevent overpayment or underpayment across diverse devices and clinical contexts.
The bill centers on creating a clear, CMS-driven pathway for determining when AI-enabled remote monitoring devices qualify for Part B payment. While this can accelerate adoption, it also depends on the substance of the forthcoming guidance and how it interfaces with existing CPT codes, coding guidance, and payer policies across Medicare and private plans.
A key risk is that guidance could be broad or open to interpretation, leading to uneven implementation across regions or payers. Data privacy and cybersecurity considerations tied to AI-driven data transmission and remote monitoring must be managed within the broader CMS and patient-protection framework.
The act does not itself alter the payment amounts or create new coverage mandates; its value lies in establishing a formal process to guide decision-making for AI-enabled devices moving through the Medicare system.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.